Calicheamicin

A potent antitumor antibiotic

Calicheamicin

File:Calicheamicin gamma 1 3D spacefill.png

Calicheamicin gamma 1 3D spacefill

File:Iterative PKS.png

Iterative PKS

File:Calicheamicin pathway.png

Calicheamicin pathway

Calicheamicin is a potent antibiotic and antitumor agent belonging to the class of enediynes. It is produced by the bacterium Micromonospora echinospora and is known for its ability to cleave DNA with high specificity and efficiency. Calicheamicin is one of the most potent cytotoxic agents known and has been utilized in the development of antibody-drug conjugates for targeted cancer therapy.

Structure

Calicheamicin is characterized by its unique molecular structure, which includes an enediyne core. This core is responsible for its DNA-cleaving activity. The molecule also contains a trisulfide linkage and a sugar moiety, which contribute to its binding affinity and specificity for DNA. The enediyne core undergoes a Bergman cyclization to form a highly reactive diradical species that abstracts hydrogen atoms from the DNA backbone, leading to strand scission.

Mechanism of Action

The mechanism of action of calicheamicin involves its binding to the minor groove of DNA, followed by activation of the enediyne core. Upon activation, the enediyne undergoes a cycloaromatization reaction, generating a diradical species. This diradical abstracts hydrogen atoms from the deoxyribose sugar in the DNA backbone, resulting in double-strand breaks. These breaks are lethal to cells, making calicheamicin an effective cytotoxic agent.

Clinical Applications

Calicheamicin has been utilized in the development of gemtuzumab ozogamicin, an antibody-drug conjugate used in the treatment of acute myeloid leukemia (AML). In this conjugate, calicheamicin is linked to an antibody that targets the CD33 antigen on leukemia cells, allowing for targeted delivery of the cytotoxic agent. This targeted approach minimizes damage to normal cells and enhances the therapeutic index of the drug.

Challenges and Research

Despite its potent activity, the clinical use of calicheamicin is limited by its toxicity and the development of resistance. Research is ongoing to develop new formulations and delivery methods to improve its therapeutic window. Efforts are also being made to engineer calicheamicin derivatives with improved selectivity and reduced side effects.

Related Pages

• Enediyne
• Antibody-drug conjugate
• Acute myeloid leukemia
• DNA
• Antibiotic

Types of antibacterials